Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience

Aim:Gastrointestinal stromal tumors (GISTs) are extremely rare. In this study, we aimed to analyze the factors affecting disease-free survival (DFS) in patients operated for non-metastatic gastric GIST (gGIST).Methods:This was a retrospective analysis of 34 patients with resectable gGIST who were fo...

Full description

Bibliographic Details
Main Authors: Ayşegül Sakin, Mehmet Naci Aldemir
Format: Article
Language:English
Published: Galenos Yayinevi 2020-09-01
Series:Haseki Tıp Bülteni
Subjects:
Online Access: http://www.hasekidergisi.com/archives/archive-detail/article-preview/factors-affecting-recurrence-free-survival-in-gast/40227
_version_ 1797913280932478976
author Ayşegül Sakin
Mehmet Naci Aldemir
author_facet Ayşegül Sakin
Mehmet Naci Aldemir
author_sort Ayşegül Sakin
collection DOAJ
description Aim:Gastrointestinal stromal tumors (GISTs) are extremely rare. In this study, we aimed to analyze the factors affecting disease-free survival (DFS) in patients operated for non-metastatic gastric GIST (gGIST).Methods:This was a retrospective analysis of 34 patients with resectable gGIST who were followed up and treated at the oncology clinic between 2008 and 2019. Patients with metastatic disease and non-gastric disease and those aged <18 years were excluded.Results:Seventeen (50%) patients were male. The median age was 64 years. According to Miettinen Risk Scores, seven patients were (20.6%) in very low-risk group, five (14.7%) in low-risk group, 17 (50%) in moderate-risk group, and five (14.7%) patients were in high-risk group. Adjuvant therapy was given in 11 (32.4%) patients. The 5- and 10-year DFS rates were same as 79.2%. The 5- and 10-year overall survival rates were 90.9% and 85.6%, respectively. In multivariate analysis, presence of necrosis [Hazard rate (HR)=9.5], being in high-risk group (HR=27.2), Ki-67 (HR=1.03), and receiving adjuvant therapy (HR=0.51) were factors affecting DFS.Conclusion:We assume that adjuvant therapy should be given in high-risk patients operated for gGIST in the presence of necrosis and high Ki-67.
first_indexed 2024-04-10T12:09:24Z
format Article
id doaj.art-bd63118e88af4714b2399ac279bd4d80
institution Directory Open Access Journal
issn 1302-0072
2147-2688
language English
last_indexed 2024-04-10T12:09:24Z
publishDate 2020-09-01
publisher Galenos Yayinevi
record_format Article
series Haseki Tıp Bülteni
spelling doaj.art-bd63118e88af4714b2399ac279bd4d802023-02-15T16:16:05ZengGalenos YayineviHaseki Tıp Bülteni1302-00722147-26882020-09-0158432733210.4274/haseki.galenos.2020.615213049054Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center ExperienceAyşegül Sakin0Mehmet Naci Aldemir1 Van Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Van, Türkiye Yüzüncü Yıl Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, Van, Türkiye Aim:Gastrointestinal stromal tumors (GISTs) are extremely rare. In this study, we aimed to analyze the factors affecting disease-free survival (DFS) in patients operated for non-metastatic gastric GIST (gGIST).Methods:This was a retrospective analysis of 34 patients with resectable gGIST who were followed up and treated at the oncology clinic between 2008 and 2019. Patients with metastatic disease and non-gastric disease and those aged <18 years were excluded.Results:Seventeen (50%) patients were male. The median age was 64 years. According to Miettinen Risk Scores, seven patients were (20.6%) in very low-risk group, five (14.7%) in low-risk group, 17 (50%) in moderate-risk group, and five (14.7%) patients were in high-risk group. Adjuvant therapy was given in 11 (32.4%) patients. The 5- and 10-year DFS rates were same as 79.2%. The 5- and 10-year overall survival rates were 90.9% and 85.6%, respectively. In multivariate analysis, presence of necrosis [Hazard rate (HR)=9.5], being in high-risk group (HR=27.2), Ki-67 (HR=1.03), and receiving adjuvant therapy (HR=0.51) were factors affecting DFS.Conclusion:We assume that adjuvant therapy should be given in high-risk patients operated for gGIST in the presence of necrosis and high Ki-67. http://www.hasekidergisi.com/archives/archive-detail/article-preview/factors-affecting-recurrence-free-survival-in-gast/40227 gastrointestinal stromal tumorgastricadjuvant therapysurvival
spellingShingle Ayşegül Sakin
Mehmet Naci Aldemir
Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
Haseki Tıp Bülteni
gastrointestinal stromal tumor
gastric
adjuvant therapy
survival
title Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
title_full Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
title_fullStr Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
title_full_unstemmed Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
title_short Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
title_sort factors affecting recurrence free survival in gastric gastrointestinal stromal tumors a single center experience
topic gastrointestinal stromal tumor
gastric
adjuvant therapy
survival
url http://www.hasekidergisi.com/archives/archive-detail/article-preview/factors-affecting-recurrence-free-survival-in-gast/40227
work_keys_str_mv AT aysegulsakin factorsaffectingrecurrencefreesurvivalingastricgastrointestinalstromaltumorsasinglecenterexperience
AT mehmetnacialdemir factorsaffectingrecurrencefreesurvivalingastricgastrointestinalstromaltumorsasinglecenterexperience